{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:58:37Z","timestamp":1782028717808,"version":"3.54.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/mop.0b013e32835bf77e","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T00:33:36Z","timestamp":1356741216000},"page":"23-30","source":"Crossref","is-referenced-by-count":4,"title":["New developments in the treatment of pediatric hemophilia and bleeding disorders"],"prefix":"10.1097","volume":"25","author":[{"given":"Brian R.","family":"Branchford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210206","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/pbc.23193","article-title":"Clinical advances in hemophilia management.","volume":"57","author":"Sharathkumar","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R2-5-20210206","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11585340-000000000-00000","article-title":"Current options and new developments in the treatment of haemophilia.","volume":"71","author":"Wong","year":"2011","journal-title":"Drugs"},{"key":"R3-5-20210206","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0032-1315757","article-title":"Acquired inhibitors of coagulation factors. Part I - Acquired hemophilia A.","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"R5-5-20210206","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0031-1300954","article-title":"Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges.","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"R6-5-20210206","doi-asserted-by":"crossref","first-page":"62","DOI":"10.32607\/20758251-2012-4-2-62-73","article-title":"Coagulation factor IX for hemophilia B therapy.","volume":"4","author":"Orlova","year":"2012","journal-title":"Acta Naturae"},{"key":"R10-5-20210206","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression.","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"R11-5-20210206","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2012.07.007","article-title":"Pharmaceutical therapies to recode nonsense mutations in inherited diseases.","volume":"136","author":"Lee","year":"2012","journal-title":"Pharmacol Therapeut"},{"key":"R12-5-20210206","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1182\/blood-2012-01-394411","article-title":"How we choose factor VIII to treat hemophilia.","volume":"119","author":"Mannucci","year":"2012","journal-title":"Blood"},{"key":"R13-5-20210206","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-0031-1276587","article-title":"Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited.","volume":"37","author":"Ichinose","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"R14-5-20210206","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3111\/13696998.2011.595462","article-title":"Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.","volume":"14","author":"Hay","year":"2011","journal-title":"J Med Econ"},{"key":"R15-5-20210206","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2011.02704.x","article-title":"PatientCaregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).","volume":"18","author":"Young","year":"2012","journal-title":"Haemophilia"},{"key":"R16-5-20210206","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1538-7836.2011.04549.x","article-title":"Recombinant factor VIIa analog (vatreptacog alfa activated) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.","volume":"10","author":"De Paula","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R18-5-20210206","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nbt.1995","article-title":"A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.","volume":"29","author":"Ivanciu","year":"2011","journal-title":"Nat Biotechnol"},{"key":"R19-5-20210206","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11684-011-0159-1","article-title":"Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.","volume":"5","author":"Wu","year":"2011","journal-title":"Front Med"},{"key":"R20-5-20210206","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/hum.2012.088","article-title":"Recent progress in gene therapy for hemophilia.","volume":"23","author":"Chuah","year":"2012","journal-title":"Human Gene Ther"},{"key":"R21-5-20210206","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/mt.2010.277","article-title":"Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector.","volume":"19","author":"Kantor","year":"2011","journal-title":"Mol Ther"},{"key":"R22-5-20210206","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat Rev Genet"},{"key":"R23-5-20210206","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"R24-5-20210206","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua).","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"R25-5-20210206","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"key":"R26-5-20210206","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood.V118.21.3124.3124","article-title":"Employing factor IX variants to avoid limitations imposed by immune recognition of AAV vector in hemophilia B gene therapy abstract.","volume":"118","author":"Monahan","year":"2011","journal-title":"Blood"},{"key":"R27-5-20210206","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther"},{"key":"R28-5-20210206","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1073\/pnas.1015571108","article-title":"Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII.","volume":"108","author":"Hu","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"R29-5-20210206","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"R30-5-20210206","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2011.08925.x","article-title":"Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.","volume":"156","author":"Scott","year":"2012","journal-title":"Br J Haematol"},{"key":"R31-5-20210206","doi-asserted-by":"crossref","first-page":"e37671","DOI":"10.1371\/journal.pone.0037671","article-title":"Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.","volume":"7","author":"Sack","year":"2012","journal-title":"PLoS One"},{"key":"R32-5-20210206","first-page":"49","article-title":"Treatment of patients with von Willebrand disease.","volume":"2","author":"Tuohy","year":"2011","journal-title":"J Blood Med"},{"key":"R33-5-20210206","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14712598.2012.667398","article-title":"Biological therapies for von Willebrand disease.","volume":"12","author":"Favaloro","year":"2012","journal-title":"Expert Opin Biol Ther"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0b013e32835bf77e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:42:42Z","timestamp":1620963762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201302000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e32835bf77e","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}